Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings (Nasdaq: ASRT) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close.
Management will host a live webcast and earnings call at 4:30 p.m. Eastern Time; telephone dial-in and a webcast replay (available ~two hours after the call) are provided on the company investor website.
Assertio Holdings (NASDAQ: ASRT) announced that as of January 12, 2026 Nasdaq has determined the company has regained compliance with all applicable listing requirements.
Nasdaq confirmed Assertio met the Minimum Bid Price Rule requiring a minimum bid of $1.00 per share for at least ten consecutive days, and that the matter is now closed. Management said compliance was achieved following the December 2025 reverse stock-split, while preserving capital allocation flexibility.
Assertio (Nasdaq: ASRT) announced publication in The Oncologist of a phase 1, multicenter (13 U.S. sites) trial (NCT04187898) testing same-day dosing of Rolvedon (eflapegrastim-xnst) given 30 minutes after TC chemotherapy in early-stage breast cancer. In 53 enrolled patients (49 completed), the mean time to ANC recovery in Cycle 1 was 1.8 days. Febrile neutropenia occurred in 1 patient; no neutropenic complications, hospitalizations, or antibiotic therapy were reported. The publication follows a December 2024 SABCS presentation. The company noted no new safety signals; randomized trials were not conducted.
Assertio (NASDAQ: ASRT) filed a certificate amendment on December 19 to implement a 1-for-15 reverse stock split of its common stock, effective 12:01 a.m. ET on December 26, 2025. Trading will be on a split-adjusted basis when markets open December 26, 2025, and the ticker ASRT will remain unchanged. The new CUSIP will be 04546C 304. The company said the reverse split aims to maintain its Nasdaq listing and support commercial progress around Rolvedon. Proportionate adjustments will be made to the conversion rate of the company’s 6.5% Convertible Senior Notes due 2027 and to shares authorized/reserved under equity plans and outstanding awards. No fractional shares will be issued; fractional entitlements will be paid in cash based on the December 24, 2025 Nasdaq closing price. Continental Stock Transfer & Trust will act as exchange agent.
Assertio (Nasdaq: ASRT) reported third quarter 2025 results and provided updated full‑year guidance on November 10, 2025. Key highlights include Rolvedon net product sales of $38.6M in Q3 (up from $15.0M a year earlier) and Adjusted EBITDA of $20.9M for the quarter. The company narrowed FY2025 guidance to Net Product Sales $110.0M–$112.0M and Adjusted EBITDA $14.0M–$16.0M. Cash and short‑term investments were $93.4M at September 30, 2025. Management advanced integration to consolidate subsidiaries and promoted Paul Schwichtenberg to President & COO.
Assertio (Nasdaq: ASRT) appointed director Mark L. Reisenauer as CEO effective immediately; current CEO Brendan P. O’Grady will depart.
The company said it will release third-quarter 2025 results on November 10, 2025 after market close and host a live webcast at 4:30 p.m. ET the same day. Management expects to update guidance within the current range on that call. Reisenauer joined the Board in January 2025 and has over 30 years of commercial experience, including growing U.S. commercial sales to nearly $5 billion at Astellas.
Assertio Holdings (NASDAQ: ASRT) presented groundbreaking real-world study data for SYMPAZAN® (clobazam) Oral Film at the 150th Annual Meeting of the American Neurological Association. The study, involving 181 epilepsy patients including 29 with Lennox-Gastaut Syndrome (LGS), marks the first real-world evidence of how the medicine is used in clinical practice.
The research revealed that LGS patients were typically younger (13.6 years vs. 21.1 years in the epilepsy group) and more frequently switched from other clobazam formulations. SYMPAZAN, the only FDA-approved oral film formulation of clobazam, is specifically designed for patients two years and older who have difficulty swallowing tablets or liquids.
Assertio Holdings (Nasdaq: ASRT) will present new data from a real-world evidence study of SYMPAZAN at the 150th Annual Meeting of the American Neurological Association (ANA2025). SYMPAZAN is the only FDA-approved oral film formulation of clobazam for treating seizures associated with Lennox-Gastaut syndrome in patients aged two and older.
The presentation will take place on September 15, 2025, from 12:00 – 7:30 p.m. ET at the Baltimore Marriott Waterfront. The abstract titled "Real-World Evidence Study of Patients with Lennox-Gastaut Syndrome Taking Clobazam Oral Soluble Film" will focus on patient demographics, medications, and comorbidities. Detailed study findings will be released on the presentation day, following ANA2025 embargo policy.
Assertio Holdings (NASDAQ: ASRT) announced its participation in two upcoming investor conferences in New York City during September 2025. The management team will host investor meetings at the HC Wainwright Conference on September 10, 2025, at the Lotte New York Palace Hotel, and at the Lake Street Capital Markets BIG9 Conference on September 11, 2025, at the Yale Club New York City.
Interested investors can register and request meetings through their respective HC Wainwright or Lake Street representatives.
Assertio Holdings (NASDAQ: ASRT) reported Q2 2025 financial results with total net product sales of $28.8 million, down from $30.7 million in Q2 2024. The company's cash position strengthened to $98.2 million, up from $87.3 million in Q1 2025.
Key product performance included Rolvedon sales of $16.1 million (up from $15.1 million), Sympazan sales of $3.2 million (up from $2.7 million), and Indocin sales of $3.0 million (down from $6.9 million). The company reported a GAAP net loss of $16.4 million but achieved Adjusted EBITDA of $5.6 million.
Assertio narrowed its 2025 guidance, projecting net product sales of $108.0-118.0 million and adjusted EBITDA of $11.0-19.0 million. The company continues its transformation strategy, including streamlining operations and focusing on core growth assets.